|
|
|
Daniel DeSalvo, MD
Pediatric Endocrinologist
Baylor College of Medicine
Texas Children's Hospital
|
|
Jeffrey Dunn, PharmD, MBA
(Formerly) Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management
|
|
Troy Ross, MSM
President & CEO
Mid-America Coalition on Health Care
|
|
TARGET AUDIENCE
|
- Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, nurses, care managers, and other managed care and payer organization professionals
|
|
PROGRAM OVERVIEW
|
Innovations in CGM technology have the promise of improved glucose control and quality of life. Several studies have demonstrated the safety, efficacy, and cost effectiveness of this technological revolution. The current COVID-19 pandemic has forced us to reconsider the ways in which effective diabetes management is delivered during these challenging times - both in the inpatient and outpatient setting. The availability of connected CGM data facilitates effective diabetes management remotely. Recently, the FDA has allowed for the use of real-time CGM (rtCGM) in hospital settings to support COVID-19 healthcare-related efforts during the current pandemic. Remote patient monitoring facilitates timely medical intervention and has the potential to limit staff exposure to the novel coronavirus and preserve vital personal protective equipment (PPE). This program will elucidate the burden of diabetes and describe multifaceted clinical and administrative strategies to promote quality care and manage costs while improving outcomes for affected plan members.
|
|
EDUCATIONAL OBJECTIVES
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Describe the benefits of remote monitoring in the management of hospitalized patients with COVID-19 and dysglycemia
- Assess the value of rtCGM in improving quality of care and reducing societal health-costs in a new era of digital health
- Characterize the role of rtCGM as part of an employer-driven diabetes management strategy
- Identify appropriate benefit design strategies to reduce healthcare system burden and improve quality, clinical, and economic outcomes
|
|
AGENDA
|
|
1:00 PM
|
Opening Comments/Overview
Jeffrey Dunn, PharmD, MBA
|
|
1:05 PM
|
Clinical and Economic Consequences of Imprecise Glycemic Control in a New Era of Telehealth Management
Daniel DeSalvo, MD
|
|
1:35 PM
|
Implementing CGM: Real World Insights
Jeffrey Dunn, PharmD, MBA
|
|
1:55 PM
|
Optimal Clinical and Economic Outcomes in Diabetes: The Employer Perspective
Troy Ross, MSM
|
|
2:15 PM
|
Audience Q&A Session
Key Takeaways and Closing Comments
|
|
2:30 PM
|
Adjournment
|
ACCREDITATION INFORMATION
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Credit
 |
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0816-9999-20-137-L01-P
This activity is certified as Knowledge-based CPE.
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Faculty |
Reported Financial Relationships |
| Daniel DeSalvo, MD |
TBD |
| Jeffrey Dunn, PharmD, MBA |
No financial interest/relationships relating to the topic of this activity |
| Troy Ross, MSM |
No financial interest/relationships relating to the topic of this activity |
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Content Manager |
Reported Financial Relationships |
| Impact Education, LLC. Content Managers |
No financial interest/relationships relating to the topic of this activity |
| MER Content Managers |
No financial interest/relationships relating to the topic of this activity |
Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.
Fee Information
There is no fee for this educational activity.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
| | | | |
